These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8212440)

  • 41. Relative potency and arteriovenous selectivity of nitrovasodilators on human blood vessels: an insight into the targeting of nitric oxide delivery.
    MacAllister RJ; Calver AL; Riezebos J; Collier J; Vallance P
    J Pharmacol Exp Ther; 1995 Apr; 273(1):154-60. PubMed ID: 7714761
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Blood gas changes in the corpora cavernosa: metabolic and histomorphometric implications in the patient with erectile dysfunction.
    Sasso F; Falabella R; Gentile G; Servello C; Gulino G
    J Urol; 2003 Jun; 169(6):2270-4. PubMed ID: 12771768
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Erectile dysfunction in the case of cardiovascular disease].
    Desvaux P
    Presse Med; 2005 Jul; 34(13 Suppl):24-6. PubMed ID: 16158027
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Place of intra-urethral prostaglandin E1 for the treatment of erectile dysfunction].
    Amar E
    Contracept Fertil Sex; 1999; 27(7-8):548-52. PubMed ID: 10495573
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of SIN-1 on isolated canine basilar arteries.
    Katusic ZS; Vanhoutte PM
    J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S72-5. PubMed ID: 2484704
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of various nitric oxide-donating drugs on adrenergic tension of human seminal vesicles in vitro.
    Machtens S; Ckert S; Stief CG; Tsikas D; Frlich Jr; Jonas U
    Urology; 2003 Feb; 61(2):479-83. PubMed ID: 12597985
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prostaglandin E1 for treatment of erectile dysfunction.
    Urciuoli R; Cantisani TA; Carlini M; Giuglietti M; Botti FM
    Cochrane Database Syst Rev; 2004; (2):CD001784. PubMed ID: 15106162
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intracavernous injection of prostaglandin E1: the application to cavernosography and penile blood flow measurement for the diagnosis of venogenic impotence.
    Ishigooka M; Irisawa C; Watanabe H; Adachi M; Ishii N; Nakada T
    Urol Int; 1991; 46(2):193-6. PubMed ID: 2053230
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Erectile dysfunction in diabetic patients].
    Lemaire A; Alexandre B
    Presse Med; 2005 Jul; 34(13 Suppl):21-3. PubMed ID: 16158026
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A study in patients with erectile dysfunction comparing different formulations of prostaglandin E1. Alprostadil Study Group.
    Vanderschueren D; Heyrman RM; Keogh EJ; Casey RW; Weiske WH; Ogrinc FG; de Koning Gans HJ
    J Urol; 1995 Nov; 154(5):1744-7. PubMed ID: 7563337
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synergistic inhibition of human polymorphonuclear function by prostaglandin E1 and linsidomine.
    Gladis-Villanueva M; Schrör K
    J Pharm Pharmacol; 1996 Jul; 48(7):706-11. PubMed ID: 8866334
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.
    Maurice DH; Haslam RJ
    Mol Pharmacol; 1990 May; 37(5):671-81. PubMed ID: 2160060
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Evaluation of 452 patients with erectile dysfunction treated by combinations of vasoactive agents by penile injection].
    Segenreich E; Israilov S; Shmueli J; Simon D; Baniel J; Livne P
    Harefuah; 1998 May; 134(9):673-8, 750. PubMed ID: 10909609
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interaction between endothelium-derived nitric oxide and SIN-1 in human and porcine blood vessels.
    Lüscher TF; Richard V; Yang ZH
    J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S76-80. PubMed ID: 2484705
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The use of PGE1 in the treatment of erectile deficiency].
    Arena F; Peracchia G; Di Stefano C; Cortellini P
    Acta Biomed Ateneo Parmense; 1996; 67(1-2):49-53. PubMed ID: 10021734
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Prostaglandin treatment in neurological patients with erectile dysfunction].
    Conejero Sugrañes J; Muñoz Villellas A; Sarrias Lorenz F; Ramírez Garceran L
    Arch Esp Urol; 2002; 55(1):63-8. PubMed ID: 11957754
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A comparison of colour duplex ultrasonography after transurethral alprostadil and intracavernous alprostadil in the assessment of erectile dysfunction.
    Ahn HS; Lee SW; Yoon SJ; Hann HJ; Hong JM
    J Int Med Res; 2004; 32(3):317-23. PubMed ID: 15174226
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term efficacy of a new formulation of prostaglandin E1 as treatment for erectile failure.
    Godschalk M; Gheorghiu D; Chen J; Katz PG; Mulligan T
    J Urol; 1996 Mar; 155(3):915-7. PubMed ID: 8583606
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Erectile dysfunction: an overview.
    Fabbri A; Aversa A; Isidori A
    Hum Reprod Update; 1997; 3(5):455-66. PubMed ID: 9528911
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Calcitonin-gene-related peptide: a possible role in human penile erection and its therapeutic application in impotent patients.
    Stief CG; Wetterauer U; Schaebsdau FH; Jonas U
    J Urol; 1991 Oct; 146(4):1010-4. PubMed ID: 1895414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.